Angiotensin receptor blockers (ARBs), which are commonly used antihypertensives, have been proposed to lower the risk of Parkinson disease by reducing oxidative stress based on animal and in vitro studies. Thus, this study aimed to test this association in patients with newly diagnosed hypertension.
This retrospective cohort study enrolled 107,207 patients with newly diagnosed hypertension between 2001 and 2013. The hazard ratios for Parkinson disease were calculated for ARB treatment compared with those who never used ARBs and among the 5 subgroups receiving different cumulative ARB dosages.
We identified 527 (1.1%) Parkinson disease cases among patients with ARB treatment in a median observation period of 8.4 years compared to the 1,255 (2.2%) Parkinson disease cases among those without ARB treatment in a median observation period of 6.8 years. Overall, risk for developing Parkinson disease was statistically lower in the ARB-treated group with a hazard ratio of 0.56 (95% confidence interval: 0.51-0.63) than those without ARB.
ARB treatment was associated with a statistically important reduction of Parkinson disease risk in patients with newly diagnosed hypertension. Therefore, ARB may constitute an effective neuroprotective strategy to lower Parkinson disease risk in such patients.
To read this article in full you will need to make a payment
Purchase one-time access:Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
One-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:Subscribe to The American Journal of Medicine
Already a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
- Parkinson disease.Eur J Neurol. 2020; 27: 27-42
- Neuroinflammation in Parkinson's disease.Parkinsonism Relat Disord. 2012; 18: S210-S212
- Significant roles of neuroinflammation in Parkinson's disease: therapeutic targets for Parkinson's disease prevention.Arch Pharm Res. 2019; 42: 416-425
- Oxidative stress and cellular pathologies in Parkinson's disease.Mol Brain. 2017; 10: 53
- A new look at the renin-angiotensin system–focusing on the vascular system.Peptides. 2011; 32: 2141-2150
- The role of the central renin-angiotensin system in Parkinson's disease.J Renin Angiotensin Aldosterone Syst. 2010; 11: 49-56
- A role for the brain RAS in Alzheimer's and Parkinson's diseases.Front Endocrinol (Lausanne). 2013; 4: 158
- Brain renin-angiotensin system and dopaminergic cell vulnerability.Front Neuroanat. 2014; 8: 67
- Effects of ANG II type 1 and 2 receptors on oxidative stress, renal NADPH oxidase, and SOD expression.Am J Physiol Regul Integr Comp Physiol. 2003; 285: R117-R124
- Brain angiotensin enhances dopaminergic cell death via microglial activation and NADPH-derived ROS.Neurobiol Dis. 2008; 31: 58-73
- Renin-angiotensin system as a potential target for new therapeutic approaches in Parkinson's disease.Expert Opin Investig Drugs. 2017; 26: 1163-1173
- Angiotensin type-1-receptor antagonists reduce 6-hydroxydopamine toxicity for dopaminergic neurons.Neurobiol Aging. 2007; 28: 555-567
- The inflammatory response in the MPTP model of Parkinson's disease is mediated by brain angiotensin: relevance to progression of the disease.J Neurochem. 2009; 109: 656-669
- New and old roles of the peripheral and brain renin-angiotensin-aldosterone system (RAAS): Focus on cardiovascular and neurological diseases.Int J Cardiol. 2017; 227: 734-742
- Antihypertensive agents and risk of Parkinson's disease: a nationwide cohort study.PLoS One. 2014; 9: e98961
- Use of antihypertensives and the risk of Parkinson disease.Neurology. 2008; 70: 1438-1444
- L-type calcium channel blockers and Parkinson disease in Denmark.Ann Neurol. 2010; 67: 600-606
- Association of blood pressure and hypertension with the risk of Parkinson disease: the National FINRISK Study.Hypertension. 2011; 57: 1094-1100
- Association between hypertension and the risk of Parkinson's disease: a meta-analysis of analytical studies.Neuroepidemiology. 2019; 52: 181-192
- Use of antihypertensives and the risk of Parkinson disease.Neurology. 2009; 72: 578-579
- Dopamine-angiotensin interactions in the basal ganglia and their relevance for Parkinson's disease.Mov Disord. 2013; 28: 1337-1342
- Angiotensin II receptor binding associated with nigrostriatal dopaminergic neurons in human basal ganglia.Ann Neurol. 1992; 32: 339-344
- Molecular determinants of selective dopaminergic vulnerability in Parkinson's disease: an update.Front Neuroanat. 2014; 8: 152
- Elevated mitochondrial bioenergetics and axonal arborization size are key contributors to the vulnerability of dopamine neurons.Curr Biol. 2015; 25: 2349-2360
- Selective neuronal vulnerability in Parkinson disease.Nat Rev Neurosci. 2017; 18: 101-113
- Oxidative stress in the aging substantia nigra and the etiology of Parkinson's disease.Aging Cell. 2019; 18: e13031
- Brain angiotensin and dopaminergic degeneration: relevance to Parkinson's disease.Am J Neurodegener Dis. 2012; 1: 226-244
- The AT2 receptor–a matter of love and hate.Peptides. 2005; 26: 1401-1409
- The epidemiology of Parkinson's disease: risk factors and prevention.Lancet Neurol. 2016; 15: 1257-1272
- Cerebral small vessel disease and incident parkinsonism.Neurology. 2015; 85: 1569-1577
- Small vessel disease.Front Neurol. 2019; 10: 1020
Published online: May 14, 2022
Conflicts of Interest: None.
Authorship: All authors had access to the data and a role in writing this manuscript.
© 2022 Elsevier Inc. All rights reserved.